ORIGINAL PAPER
Anakinra in the treatment of rheumatoid arthritis in adult patients with an inadequate response to methotrexate. Systematic review and meta-analysis
Online publication date: 2013-04-29
Reumatologia 2013;51(2):119-126
KEYWORDS
ABSTRACT
Background: Anakinra is an interleukin-1 receptor antagonist (IL-1Ra) that blocks the biological activity of IL-1, including inflammation. Anakinra in combination with methotrexate (MTX) is indicated for reduction in signs and symptoms in active rheumatoid arthritis, in adults who have failed one or more disease-modifying antirheumatic drugs (DMARDs).
Material and methods: According to the rules of evidence-based medicine popularized by The Cochrane Collaboration, a systematic review of medical literature has been performed in order to assess clinical efficacy and safety of the therapy. The review yielded three randomized clinical studies which compared the administration of anakinra in combination with MTX (or other DMARDs) to placebo with MTX.
Results: Moderate clinical efficacy defined as ACR20, ACR50 and ACR70 response and safety profile of anakinra in combination with MTX or other DMARDs was proven in most studies mentioned and confirmed by the results of the meta-analysis performed.
Conclusions: Injection site reactions were the most common adverse events frequently leading to withdrawal.
Material and methods: According to the rules of evidence-based medicine popularized by The Cochrane Collaboration, a systematic review of medical literature has been performed in order to assess clinical efficacy and safety of the therapy. The review yielded three randomized clinical studies which compared the administration of anakinra in combination with MTX (or other DMARDs) to placebo with MTX.
Results: Moderate clinical efficacy defined as ACR20, ACR50 and ACR70 response and safety profile of anakinra in combination with MTX or other DMARDs was proven in most studies mentioned and confirmed by the results of the meta-analysis performed.
Conclusions: Injection site reactions were the most common adverse events frequently leading to withdrawal.
REFERENCES (25)
1.
Kontny E. Patogeneza reumatoidalnego zapalenia stawów. Część I – odpowiedź nabyta, uwarunkowania genetyczne i środowiskowe. Reumatologia 2011; 49: 47-54.
2.
Tłustochowicz W, Brzosko M, Filipowicz-Sosnowska A i wsp. Stanowisko Zespołu Ekspertów Konsultanta Krajowego ds. Reumatologii w sprawie diagnostyki i terapii reumatoidalnego zapalenia stawów. Reumatologia 2008; 46: 111-114.
3.
Rell-Bakalarska M. Osteoporoza w reumatoidalnym zapaleniu stawów. Postępy Nauk Medycznych 2008; 6: 381-388.
4.
Mackiewicz S. Reumatoidalne zapalenie stawów – aspekty immunobiologiczne. Reumatologia 2011; 49: 223-230.
5.
Rooney M, Symons JA, Duff GW. Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol Int 1990; 10: 217-219.
6.
Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Therapeutics 2004; 26: 1960-1975.
9.
Bijlsma MD, Bijlsma J. Optymalne leczenie reumatoidalnego zapalenia stawów – zalecenia EULAR dla praktyki klinicznej. Medycyna Praktyczna 2010; 9: 35-49.
10.
Smolen J, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975.
13.
Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-624.
14.
Cohen SB, Woolley JM, Chan W; Anakinra 960180 Study Group. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 225-231.
15.
Cohen SB, Moreland LW, Cush JJ, et al.; 990145 Study Group. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63: 1062-1068.
16.
Bao J, Yue T, Liu W, et al. Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis. Clin Rheumatol 2011; 30: 697-701.
17.
Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48: 927-934.
18.
Tesser J, Fleischmann R, Dore R, et al.; 990757 Study Group. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. .
20.
Niu X, He D, Deng S, et al. Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis. Mol Immunol 2011; 49: 290-296.
21.
Karanikolas G, Charalambopoulos D, Vaiopoulos G, et al. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. Rheumatology (Oxford) 2008; 47: 1384-1388.
22.
Le Loët X, Nordström D, Rodriguez M, et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. J Rheumatol 2008; 35: 1538-1544.
23.
den Broeder AA, de Jong E, Franssen MJ, et al. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006; 65: 760-762.
24.
Galloway JB, Hyrich KL, Mercer LK, et al.; BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2011; 50: 1341-1342.
25.
Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25-32.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
